## SENTARA HEALTH PLANS

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-668-1550</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

<u>For Medicare Members:</u> Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <a href="https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx">https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx</a>. Additional indications may be covered at the discretion of the health plan.

Drug Requested: Panhematin® (hemin for injection) J1640 (Medical)

☐ Member is 16 years of age or older

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.	
Member Name:	
Member Sentara #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	Fax Number:
NPI #:	
DRUG INFORMATION: Authorization may	y be delayed if incomplete.
Drug Form/Strength:	
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight (if applicable):	Date weight obtained:
	frame does not jeopardize the life or health of the member tion and would not subject the member to severe pain.
CLINICAL CRITERIA: Check below all the support each line checked, all documentation, include provided or request may be denied.	at apply. All criteria must be met for approval. To ding lab results, diagnostics, and/or chart notes, must be
Initial Authorization: 14 days	

(Continued on next page)

PA Panhematin (Medical)(CORE) (Continued from previous page)

	Prescribed by or in consultation with an obstetrics/gynecology specialist
	Member has a diagnosis of acute intermittent porphyria related to the menstrual cycle
	Provider has submitted documentation of elevation of urinary porphobilinogen (PBG) <u>AND</u> delta-aminolevulinic acid (ALA)
	Initial carbohydrate therapy has been documented to be inadequate
	Requested medication dosing is prescribed in accordance with the United States Food and Drug Administration (FDA) approved labeling (1 to 4 mg/kg/day IV for 3 to 14 days; maximum: 6 mg/kg per 24 hours)
supp	uthorization: 14 days. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ded or request may be denied.
	Member has previously been receiving Panhematin
	Provider has submitted documentation which confirms member has experienced a positive response to Panhematin therapy demonstrated by clinical improvement, or by a decrease in at least <u>ONE</u> of the following compounds in urine: ALA, PBG – porphobilinogen, uroporphyrin, coproporphyrin)
	Requested medication dosing is prescribed in accordance with the United States Food and Drug Administration (FDA) approved labeling (1 to 4 mg/kg/day IV for 3 to 14 days; maximum: 6 mg/kg per 24 hours)
Medication being provided by: Please check applicable box below.	
<b>u</b> ]	Location/site of drug administration:
ľ	NPI or DEA # of administering location:
	<u>OR</u>
<b>-</b> \$	Specialty Pharmacy
	r urgent reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard view would subject the member to adverse health consequences. Sentara's definition of urgent is a lack of

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*

treatment that could seriously jeopardize the life or health of the member or the member's ability to regain

maximum function.